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T cells as a therapy for inflammatory
disorders. If Treg cells are actually
able to induce or expand pathogenic
Th17 cells in vivo, they may do more
harm than good in some situations. It
will be imperative to establish the role,
if any, of Treg cells in promoting inflam-
mation, and also to properly identify
which T helper cell subset predomi-
nates in different human disease set-
tings before attempting such therapy.
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In this issue of Immunity, Voigt et al. (2007) and Lu et al. (2007) extend the understanding of the
consequences of missing-self recognition in immune evasion and immune cell regulation via
NKRP-1 and CD94-NKG2A inhibitory receptors, respectively.Natural killer (NK) cells are lympho-
cytes of the innate immune system
that are known for their role in the con-
trol of viral infections and tumor devel-
opment. The dissection of NK-cell-
recognition strategies has been pivotal
for the emergence of the ‘‘dynamic
equilibrium’’ concept. NK cells are
equipped with a variety of activating
and inhibitory receptors, the engage-
ment of which regulates NK-cell activ-
ities. It is thus the integration of antag-
onistic pathways upon interaction with
neighboring cells that dictates whether
NK cells are activated or not. NK-cell-
activating receptors include cytokinereceptors, integrins, and receptors
that detect the presence of infectious
nonself ligands (e.g., via Ly49H in the
mouse) or stress-induced self ligands
(e.g., via NKG2D). The inhibitory re-
ceptors that have been most studied
so far are major histocompatibility
complex (MHC)-class-1-specific re-
ceptors. NK cells loose their inhibition
when encountering MHC-class-I-defi-
cient hematopoietic cells in several
in vitro and in vivo models. As a conse-
quence, NK cells have been identified
as recognizing missing-self on hema-
topoietic cells (Ljunggren and Ka¨rre,
1990). The MHC-class-I-specific in-Immunhibitory receptors include the killer-
cell immunoglobulin-like receptors
(KIR) in humans, the lectin-like Ly49 di-
mers in the mouse, and the lectin-like
CD94-NKG2A heterodimers in both
species. A conserved feature of these
inhibitory receptors resides in the
presence of one or two intracytoplas-
mic inhibitory signaling domains, the
immunoreceptor tyrosine-based inhi-
bition motifs (ITIMs). By interacting
with MHC class I molecules that are
constitutively expressed by most cells
in steady-state conditions but may be
lost upon stress, inhibitory MHC class
I receptors provide a way for NK cellsity 26, May 2007 ª2007 Elsevier Inc. 549
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PreviewsFigure 1. Multiple Roles for NK-Cell Inhibitory Receptors
NK cells are equipped with various cell surface inhibitory receptors that participate in sensing of
their environment. Inhibitory receptors that are specific for MHC class Ia molecules, (KIR in
humans, Ly49 molecules in the mouse) are involved in the education of NK cells to missing-self.
These inhibitory MHC class I receptor participate in shaping of the NK-cell functional repertoire.
CD94-NKG2A heterodimers recognize MHC class Ib molecules (Qa-1 in the mouse, HLA-E in
humans), and their engagement dampens NK-cell effector function (i.e cytotoxicity and cytokine
secretion). Cantor et al. now show that NK cells kill autologous activated CD4+ T cells, unless
the latter express Qa-1. In addition, NK-cell tolerance to self is ensured by other inhibitory recep-
tors such as NKR-P1B that interacts with Clr-b in the mouse, and human NKRP-1 that interacts
with LLT-1. Voigt et al. (2007) now show that a cell-surface molecule encoded by the rat CMV,
RCTL, acts a receptor for the rat inhibitory receptor NKR-P1B.to ensure tolerance to self, while allow-
ing toxicity toward stressed cells. Be-
sides their role in the control of NK-cell
effector function, MHC-class-I-specific
inhibitory receptors have also been
shown to contribute to NK-cell matu-
ration. Indeed, the recognition of self
MHC class I by inhibitory receptors
during NK-cell development is re-
quired for the capacity of NK cells to
subsequently recognize missing-self
MHC class I (Anfossi et al., 2006)
(Figure 1).
Other inhibitory cell-surface recep-
tors have been described in a variety
of cell types, such as the NKR-P1 mol-
ecules (encoded by Klrb1) in NK-cell
and T cell subsets. Klrb1 genes belong
to a multigenic and mutiallelic gene
family in rodents, whereas only one hu-
man KLRB1 ortholog has been found
(encoding NKR-P1A). The identifi-
cation of osteoclast inhibitory lectin
(Ocil; also called C type lectin-related
b [Clr-b]) as a ligand for mouse
NKR-P1B revealed several interesting
features (Carlyle et al., 2004; Iizuka
et al., 2003). First, the genes encoding
NKR-P1 molecules and their Clr-b550 Immunity 26, May 2007 ª2007 Elsevligands are intermingled within the NK
gene complex (NKC) in rodents and
humans. Second, NKR-P1 molecules
and their ligands are C type lectin ho-
modimers. In this issue of Immunity,
Voigt et al. (2007) identify RCTL, a lec-
tin encoded by rat cytomegalovirus
(RCMV), as a ligand for the rat inhibi-
tory NKR-P1B. The first clue for these
findings came from the homology be-
tween RCTL and mouse Clr-b family
members. Remarkably, engagement
of RCTL with NKR-P1B dampens
NK-cell activation, providing a MHC-
class-I-independent mechanism for
RCMV to evade NK-cell control (Voigt
et al., 2007). Previous results had sug-
gested a role for viral MHC class I ho-
mologs in the subversion of inhibitory
receptors, such as UL-18, a human
CMV product that binds the inhibitory
receptor LIR-1 (ILT-2, LILRB1) or
m157, a product of mouse CMV that
binds the inhibitory Ly49I receptor in
129/J mice. Although appealing, this
hypothesis remained to be strength-
ened. The RCTL:NKR-P1B interaction
thus now provides compelling evi-
dence that inhibitory receptors canier Inc.be hijacked by pathogens, leading to
a downregulation of the immune re-
sponse. Importantly, these results
also highlight the role of NKR-
P1B:Clr-b interactions in MHC-class-
I-independent missing-self recogni-
tion. Clr-b was previously reported to
be frequently downregulated on
mouse tumor cells, hence participat-
ing in the sensitivity of tumor cells to
NK-cell attack (Carlyle et al., 2004).
Voigt et al. (2007) now show that
Clr-b is downregulated upon RCMV
infection and that RCMV fights back
against this missing-self recognition
by providing a decoy ligand for NKR-
P1B. Indeed, infection with a virus
carrying a RCTL deletion results in a
reduced viral titer in susceptible rats.
In addition, wild-type and RCTL-defi-
cient viruses present equal virulence
upon NK-cell depletion in vivo. Except
for MHC-mismatched hematopoietic
transplantations, there is still very little
evidence for a biological function of
missing-self recognition in vivo. The
correlation between the downregula-
tion of Clr-b expression on RCMV-
infected cells and the control of
RCTL-deficient RCMV infection by
NK cells strongly supports the impor-
tance of MHC-class-I-independent
missing-self (Clr-b) recognition by NK
cells in the control of a viral infection
in vivo.
New results regarding the role of
missing-self recognition are also re-
ported in this issue of Immunity (Lu
et al., 2007). Like their HLA-E orthologs
in humans, Qa-1 are nonpolymorphic
MHC class Ib molecules, which pres-
ent a restricted set of peptides, includ-
ing leader sequences of MHC class Ia
molecules. Using Qa-1-deficient and
Qa-1 knockin mutant mice, Lu et al.
(2007) now show that NK cells kill au-
tologous activated CD4+ T cells unless
the latter express surface peptide:
Qa-1 complexes. The inhibitory CD94-
NKG2A dimers expressed on NK cells
interact with peptide:Qa-1 complexes
expressed on activated CD4+ T cells
and govern the perforin-dependent
NK-cell cytotoxicity against CD4+ T
cells (Lu et al., 2007). These data are
consistent with other recent reports re-
vealing NK cells as immune regulators.
In particular, NK cells can recognize
and eliminate activated macrophages
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control of macrophages by NK cells
might participate to the onset and/or
progression of various inflammatory
disorders such as those involving he-
mophagocytic syndromes. In addition,
activated NKG2A+ NK cells kill human
immature dendritic cells (DCs), and
the upregulation of HLA-E (concomi-
tant to increased in MHC class Ia
expression) is responsible for sparing
mature DCs. This process may shape
subsequent T cell responses, particu-
larly in the lymph nodes, where
NKG2A+ cells represent the majority
of NK cells (Moretta et al., 2006). In
the same line, in bone-marrow-graft
settings supplemented with alloreac-
tive NK cells, a graft-versus-leukemia
effect was observed, but also de-
crease of graft-versus-host disease
as well as increased bone-marrow
engraftment (Ruggeri et al., 2006).
Additional data in this setting suggest
that alloreactive donor NKs contribute
to the destruction of host DCs (dimin-
ishing GVHD) and other host immune
cells (facilitating engraftment) (Ruggeri
et al., 2006). These data prompt further
examination of the role of NK cells in
the control of immune homeostasis
and investigations into the kinetics of
expression of ligands for both inhibi-
tory and activating ligands on CD4+ T
cells (and other hematopoietic cells)
during immune response. Dampening
of Qa-1 on activated CD4+ T cells in
late phases of immune responses
might induce NK-cell susceptibility
and therefore participate in the con-
traction of immune responses. These
newly discovered functions of NK cells
have been hidden for decades by the
dissection of NK-cell effector function
against microbe-infected cells and
tumors, and their relative importance
must now be evaluated in parallel.
Yet, the manipulation of NK-cell regu-
latory functions might already lead to
important clinical promises. Along
these lines, Lu et al. (2007) show that
the blocking of Qa-1 interaction with
CD94-NKG2A (via a Qa-1 R27A point
mutant that selectively prevents the
interaction between peptide:Qa-1
complexes and CD94-NKG2A, or viainjection of Qa-1 antibodies) in ex-
perimental autoimmune encephalo-
myelitis (EAE) settings inhibits the
development of the disease. These
data suggest that blocking of NKG2A:
HLA-E interactionmay represent novel
therapeutic strategies to manipulate
NK cells in patients with autoimmune
syndromes. Interestingly, the blocking
of NK-cell Ly49 inhibitory receptors
has been previously proposed to
increase NK-cell effector function
against tumor cells in vivo in themouse
(Koh et al., 2001), without adverse
effect. Thus, distinct MHC-class-I-
specific inhibitory receptors could be
targeted in different indications: (1)
the blocking of KIR inhibitory receptors
for MHC class Ia to prevent tumor pro-
gression by increasing NK-cell activity
against MHC class I+ tumors (a strat-
egy currently in phase I clinical trials
in human acute myeloid leukemia),
and (2) the blocking of CD94-NK2A
inhibitory receptors for MHC class Ib
to prevent CD4+ T cell-dependent
autoimmunity. Many issues remain to
be addressed to firmly settle the ratio-
nale of these protocols, such as the
expression profile of HLA-E in hu-
mans. Finally, it should be stressed
that the blocking of Qa-1 interaction
with CD94-NKG2A also leads to an in-
hibition of recall antigen-driven CD4+ T
cell response. This potential NK-cell-
mediated immunosuppressive effect
might appear as a serious limitation in
the therapeutic use of drugs that block
the CD94-NKG2A inhibitory function in
humans, such as NKG2A or HLA-E
antibodies.
In autoimmune diseases, it seems
that NK cells have divergent effects.
In EAE, NK cells appear to dampen
the pathogenic process by removing
activated T cells in established disease
(Lu et al., 2007). However, NK-cell
activation may favor inflammation
and therefore promote the onset of ex-
perimental diabetes models (Ogasa-
wara et al., 2004). Given that injections
of blocking NKG2D antibodies have
been proposed to cure autoimmune
diabetes (Ogasawara et al., 2004), it
is tempting to investigate further the
role of NKG2D in EAE, and the regula-Immunitory function of CD94-NKG2A on
NKG2D-dependent NK-cell effector
function. NK cells have long been con-
sidered in the search for biological
functions. The ‘‘dynamic equilibrium’’
model of NK-cell activation now
prompts us to target activating and
inhibitory NK-cell signals in various
pathological conditions. The use of in-
hibitory receptors by viruses to evade
NK-cell control might be considered
as a ‘‘natural’’ proof of principle for
the efficiency of some of these inno-
vative therapeutic strategies.
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